CRON - Cronos Group Inc.
Many marijuana stock investors have a strong positive outlook on the future of the market. If you've been watching the cannabis sector, then you know how volatile and uncertain trading can be. Yet there have been changes that give more upside to what the future of investing can hold. As cannabis is now a class 3 substance federally, more companies are making shifts in their business to get in line with this new legislation.
Cronos reported strong Q1 performance with record level revenue. International sales are driving growth and the Canadian markets are showing improvement. The company is set to acquire CanAdelaar in the Netherlands which will increase its international operations and revenue potential.
Cronos Group Inc. reported Q1 '26 revenue up 40% to $45 million, exceeding estimates. Despite strong top-line growth, CRON posted a small operating loss of $1.8 million, with net income driven by interest and FX gains. CapEx dropped sharply by 87% year-over-year to $1.9 million, reflecting tighter capital discipline.
Cronos Group Inc. (CRON:CA) Q1 2026 Earnings Call Transcript
Cronos Group NASDAQ: CRON reported record first-quarter 2026 net revenue and gross profit, with management pointing to growth in Israel, gains for its Spinach brand in Canada and continued international expansion as key drivers of the quarter.
Cronos Group (CRON) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.02 per share a year ago.
Net revenue in Q1 2026 increased by 40% year-over-year to $45. 2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada1 Ninth consecutive quarter of record net revenue in Israel, where PEACE NATURALS continues to be the number one cannabis brand2 Industry-leading balance sheet with $822 million in total cash and cash equivalents TORONTO, May 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc.
Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada 1 Ninth consecutive quarter of record net revenue in Israel, where PEACE NATURALS ® continues to be the number one cannabis brand 2 Industry-leading balance sheet with $822 million in total cash and cash equivalents TORONTO, May 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2026 first quarter business results. “Cronos delivered record net revenue and gross profit in the first quarter, as we continue to execute against our borderless products strategy and as additional supply from the expansion at Cronos GrowCo fuels our next phase of growth.
TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, announced today that Spinach STIX®, its latest innovation in its popular line-up of Spinach® pre-rolls, is now available in more provinces across Canada. Spinach STIX® is the brand's first cylindrical-style pre-roll, designed to meet surging consumer interest in this highly sought-after format in the pre-roll category1.
TORONTO, April 29, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 Annual Meeting of Shareholders on Thursday, June 18, 2026, at 11:00 a.m. ET.
Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Cronos Group (NASDAQ: CRON - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation. Institutional and Insider Ownership 36.8% of Aurinia Pharmaceuticals
Cronos Group (NASDAQ: CRON - Get Free Report) and Incannex Healthcare (NASDAQ: IXHL - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations. Analyst Recommendations This is a summary of
TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.
Marijuana stock investors are still in a position where volatility and speculation control the outcome. Especially with all the laws and regulatory changes that have transformed the cannabis industry. All of which has an impact on how the public sector behaves. When an investor speculates, whether for better or worse, it can lead to others following suit, and this typically creates more momentum for the sector as a whole. As the current state of the cannabis sector has not changed much in this regard, investors are keeping a close eye on any upward shifts in trading.
Cronos Group (NASDAQ: CRON - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation. Institutional and Insider Ownership 8.7% of Cronos
The Canadian cannabis sector continues to evolve in 2026, even as volatility remains elevated. Total Canadian cannabis sales have steadily increased in recent years, showing consistent demand growth. However, pricing pressure and competition continue to challenge margins across the industry. Still, leading companies are adapting through international expansion, scale in retail, and diversification. As a result, investors are closely watching key names for potential upside during sector recoveries.
The cannabis industry has made a tremendous impact on the world. From being once a taboo subject to now a well-respected and much more accepted industry. Even the thought of what may happen to a legal operator could shape the way marijuana stock investors think. At one point during the green rush, the fear of what could happen with no federal reform would shift how the market reacted. But as of 2026, those fears and worries have calmed down a lot.
Shares of Cronos Group CRON have staged a strong recovery over the past year. The Canada-based cannabis operator's shares have risen 46% in the said time frame, significantly outperforming the industry, as shown in the chart below.
Cronos Group Inc. (CRON:CA) Presents at The 38th Annual Roth Conference Transcript
The global cannabis industry continues evolving as legalization slowly expands across multiple regions. Investors remain focused on companies positioned for long-term growth. Canadian cannabis producers still play a major role in this global expansion.